AJO International最新文献

英文中文

Assessment of intraocular pressure changes following intravitreal injections of three anti-VEGF agents 评估玻璃体内注射三种抗血管内皮生长因子药物后的眼压变化

AJO International

Pub Date : 2024-03-16 DOI: 10.1016/j.ajoint.2024.100001

Amit Hibsh , Adiel Barak , Efrat Fleissig, Michael Regenbogen, Ainat Klein

Purpose

Intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) agents has emerged as the primary treatment for prevalent retinal diseases. Despite its efficacy, IVI may induce intraocular pressure elevation due to vitreous fluid shifts. This study aims to compare the effects of three distinct anti-VEGF agents on intraocular pressure (IOP) elevation within a single clinic setting.

Design

A prospective study, conducted at a single retinal clinic in a tertiary medical center (Tel Aviv Sourasky Medical Centre, Tel-Aviv, Israel).

Methods

Patients receiving 3 different anti VEGF medications; bevacizumab, aflibercept, and ranibizumab, were examined. IOP was measured pre- and post-injection using an iCare Pro-tonometer. Demographic parameters and ocular characteristics were collected.

Results

The study included 195 patients (average age 76.13 years; 100 males, 95 females). The medications administered were aflibercept (N = 70, 35 %), bevacizumab (N = 73, 37.4 %), and ranibizumab (N = 52, 26.7 %). In patients with a normal baseline intraocular pressure, no significant variance was observed in the post-injection versus pre-injection pressure change (delta) across medications. Conversely, in patients with higher pressure (>20 mmHg), aflibercept incited a more substantial increase than bevacizumab or ranibizumab. No correlation emerged between the pressure rise and age or lens status.

Conclusions

No significant difference was found in the increase of intraocular pressure following injection among different medications in patients with low-normal intraocular pressure. However, for patients prone to higher baseline pressure, caution is recommended with aflibercept due to a more pronounced increase. Further research is essential to comprehend the factors influencing pressure increase and their associated clinical implications.

目的抗血管内皮生长因子（anti-VEGF）药物的玻璃体内注射（IVI）已成为治疗流行性视网膜疾病的主要方法。尽管疗效显著，但静脉注射可能会因玻璃体液转移而导致眼压升高。本研究旨在比较三种不同的抗血管内皮生长因子药物在单一诊所环境下对眼压（IOP）升高的影响。方法对接受贝伐单抗、阿弗利百普和雷尼单抗三种不同抗血管内皮生长因子药物治疗的患者进行检查。使用iCare Pro眼压计测量注射前后的眼压。研究包括 195 名患者（平均年龄 76.13 岁；男性 100 人，女性 95 人）。所用药物为阿弗利百普（70例，35%）、贝伐单抗（73例，37.4%）和雷尼单抗（52例，26.7%）。在基线眼压正常的患者中，不同药物注射后与注射前的眼压变化（delta）无明显差异。相反，在眼压较高（20 mmHg）的患者中，阿夫利拜因引起的眼压升高比贝伐珠单抗或雷尼珠单抗更明显。结论在低正常眼压患者中，不同药物注射后眼压的升高没有明显差异。然而，对于基线眼压较高的患者，由于阿夫利拜因的升高更为明显，建议谨慎使用。要了解影响眼压升高的因素及其相关的临床意义，必须开展进一步的研究。

{"title":"Assessment of intraocular pressure changes following intravitreal injections of three anti-VEGF agents","authors":"Amit Hibsh , Adiel Barak , Efrat Fleissig, Michael Regenbogen, Ainat Klein","doi":"10.1016/j.ajoint.2024.100001","DOIUrl":"https://doi.org/10.1016/j.ajoint.2024.100001","url":null,"abstract":"<div><h3>Purpose</h3><p>Intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) agents has emerged as the primary treatment for prevalent retinal diseases. Despite its efficacy, IVI may induce intraocular pressure elevation due to vitreous fluid shifts. This study aims to compare the effects of three distinct anti-VEGF agents on intraocular pressure (IOP) elevation within a single clinic setting.</p></div><div><h3>Design</h3><p>A prospective study, conducted at a single retinal clinic in a tertiary medical center (Tel Aviv Sourasky Medical Centre, Tel-Aviv, Israel).</p></div><div><h3>Methods</h3><p>Patients receiving 3 different anti VEGF medications; bevacizumab, aflibercept, and ranibizumab, were examined. IOP was measured pre- and post-injection using an iCare Pro-tonometer. Demographic parameters and ocular characteristics were collected.</p></div><div><h3>Results</h3><p>The study included 195 patients (average age 76.13 years; 100 males, 95 females). The medications administered were aflibercept (<em>N</em> = 70, 35 %), bevacizumab (<em>N</em> = 73, 37.4 %), and ranibizumab (<em>N</em> = 52, 26.7 %). In patients with a normal baseline intraocular pressure, no significant variance was observed in the post-injection versus pre-injection pressure change (delta) across medications. Conversely, in patients with higher pressure (>20 mmHg), aflibercept incited a more substantial increase than bevacizumab or ranibizumab. No correlation emerged between the pressure rise and age or lens status.</p></div><div><h3>Conclusions</h3><p>No significant difference was found in the increase of intraocular pressure following injection among different medications in patients with low-normal intraocular pressure. However, for patients prone to higher baseline pressure, caution is recommended with aflibercept due to a more pronounced increase. Further research is essential to comprehend the factors influencing pressure increase and their associated clinical implications.</p></div>","PeriodicalId":100071,"journal":{"name":"AJO International","volume":"1 1","pages":"Article 100001"},"PeriodicalIF":0.0,"publicationDate":"2024-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950253524000017/pdfft?md5=2343bc89648f5d4b5dcf748054bd865c&pid=1-s2.0-S2950253524000017-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140191278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A global survey of visual symptoms in female carriers of choroideremia and X-linked retinitis pigmentosa 对脉络膜血症和 X 连锁视网膜色素变性女性携带者视觉症状的全球调查

AJO International

Pub Date : 2024-03-16 DOI: 10.1016/j.ajoint.2024.100002

Sena A Gocuk , Thomas L Edwards , Jasleen K Jolly , Lauren N Ayton

Purpose

To investigate self-reported visual impairment in a large cohort of female carriers of X-linked retinal diseases around the world, using the validated Michigan Retinal Degeneration Questionnaire (MRDQ).

Design

Cross-sectional global survey study

Methods

An online survey collecting demographic and MRDQ data was distributed to self-reported female carriers of X-linked retinal diseases, and healthy controls (females with no eye disease). Respondents indicated their visual symptoms relating to everyday activities in seven visual domains: central vision, colour vision, contrast sensitivity, scotopic function, photopic peripheral vision, mesopic peripheral vision, and photosensitivity. Mann-Whitney test was used to compared visual disability scores between female carriers and healthy controls.

Results

Two-hundred and thirty-seven female carriers of X-linked retinal diseases (74.3% choroideremia and 25.7% X-linked retinitis pigmentosa) and 100 age-matched healthy controls completed the questionnaire (median age: 51 vs. 47.5 years of age, respectively). Most female carriers resided in the USA (53.6%) and Australia (17.3%), whilst healthy controls were mostly from Australia (93%). Female carriers had significantly worse visual disability, compared to controls. Female carriers who were older than 50 years had significantly worse visual function impairment for all domains, except photosensitivity, when compared to carriers less than 50 years of age.

Conclusions

This study has shown that female carriers of choroideremia and X-linked RP report significantly worse visual symptoms, compared to healthy controls. Future studies are required to correlate MRDQ responses with clinical findings, to determine the degree of retinal changes required to impact female carriers’ quality of life.

目的通过使用经过验证的密歇根视网膜变性问卷（MRDQ），调查全球大量 X 连锁视网膜疾病女性携带者自我报告的视力损伤情况。设计横断面全球调查研究方法向自我报告的 X 连锁视网膜疾病女性携带者和健康对照组（无眼疾的女性）发放一份在线调查问卷，收集人口统计学和 MRDQ 数据。受访者从中心视力、色觉、对比敏感度、散光功能、光周边视力、中焦周边视力和光敏感度这七个视觉领域来描述与日常活动相关的视觉症状。结果237名X连锁视网膜疾病（74.3%为脉络膜血症，25.7%为X连锁色素性视网膜炎）女性携带者和100名年龄匹配的健康对照者完成了问卷调查（中位年龄分别为51岁和47.5岁）。大多数女性携带者居住在美国（53.6%）和澳大利亚（17.3%），而健康对照者大多来自澳大利亚（93%）。与对照组相比，女性携带者的视力残疾程度明显更严重。与年龄小于 50 岁的携带者相比，年龄大于 50 岁的女性携带者在除光敏感性以外的所有方面的视觉功能障碍都明显更严重。结论这项研究表明，与健康对照组相比，脉络膜血症和 X 连锁 RP 的女性携带者的视觉症状明显更严重。未来的研究需要将 MRDQ 反应与临床发现联系起来，以确定影响女性携带者生活质量所需的视网膜变化程度。

{"title":"A global survey of visual symptoms in female carriers of choroideremia and X-linked retinitis pigmentosa","authors":"Sena A Gocuk , Thomas L Edwards , Jasleen K Jolly , Lauren N Ayton","doi":"10.1016/j.ajoint.2024.100002","DOIUrl":"https://doi.org/10.1016/j.ajoint.2024.100002","url":null,"abstract":"<div><h3>Purpose</h3><p>To investigate self-reported visual impairment in a large cohort of female carriers of X-linked retinal diseases around the world, using the validated Michigan Retinal Degeneration Questionnaire (MRDQ).</p></div><div><h3>Design</h3><p>Cross-sectional global survey study</p></div><div><h3>Methods</h3><p>An online survey collecting demographic and MRDQ data was distributed to self-reported female carriers of X-linked retinal diseases, and healthy controls (females with no eye disease). Respondents indicated their visual symptoms relating to everyday activities in seven visual domains: central vision, colour vision, contrast sensitivity, scotopic function, photopic peripheral vision, mesopic peripheral vision, and photosensitivity. Mann-Whitney test was used to compared visual disability scores between female carriers and healthy controls.</p></div><div><h3>Results</h3><p>Two-hundred and thirty-seven female carriers of X-linked retinal diseases (74.3% choroideremia and 25.7% X-linked retinitis pigmentosa) and 100 age-matched healthy controls completed the questionnaire (median age: 51 vs. 47.5 years of age, respectively). Most female carriers resided in the USA (53.6%) and Australia (17.3%), whilst healthy controls were mostly from Australia (93%). Female carriers had significantly worse visual disability, compared to controls. Female carriers who were older than 50 years had significantly worse visual function impairment for all domains, except photosensitivity, when compared to carriers less than 50 years of age.</p></div><div><h3>Conclusions</h3><p>This study has shown that female carriers of choroideremia and X-linked RP report significantly worse visual symptoms, compared to healthy controls. Future studies are required to correlate MRDQ responses with clinical findings, to determine the degree of retinal changes required to impact female carriers’ quality of life.</p></div>","PeriodicalId":100071,"journal":{"name":"AJO International","volume":"1 1","pages":"Article 100002"},"PeriodicalIF":0.0,"publicationDate":"2024-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2950253524000029/pdfft?md5=7f286e8c785d5717b21e2a05bfc07087&pid=1-s2.0-S2950253524000029-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140195659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Insights on Mesenchymal to Epithelial Transition (MET) for fibrosis reversal in ocular tissue 关于间充质向上皮细胞转化（MET）以逆转眼组织纤维化的见解

AJO International

Pub Date : 2024-03-15 DOI: 10.1016/j.ajoint.2024.100003

Sarbani Hazra

引用次数: 0

首页上一页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

AJO International

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀